Kingbio's IPO on the Shenzhen Stock Exchange has been terminated. The original plan was to raise approximately 500 million yuan.

On September 11, Hangzhou Jingjie BioScience and Technology Co., Ltd. (referred to as Jingjie Bio) terminated its IPO on the ChiNext board of the Shenzhen Stock Exchange. The IPO was terminated because Jingjie Bio and the sponsor withdrew their application for listing. According to Article 62 of the "Shenzhen Stock Exchange Stock Issuance and Listing Review Rules (Amended in 2024)", the Shenzhen Stock Exchange decided to terminate the listing review. The prospectus shows that Jingjie Bio's core technology is protein analysis. By providing protein omics technology services and antibody reagent products, the company serves basic research in life sciences, drug development, and clinical diagnosis and treatment. Since its establishment in 2010, the company has been deeply involved in the proteomics industry, using mass spectrometry as its core tool, combining antibody reagent products, integrating multiple interdisciplinary fields such as biochemistry, immunology, molecular biology, and bioinformatics. They have established an organic integrated business layout of "high-throughput proteomics analysis + high-specificity antibody development", making them a pioneer in providing a comprehensive solution for proteomics analysis covering protein "discovery", "validation", and "detection" in the industry. Based on a profound understanding of the biological significance of post-translational modifications of proteins and the technical advantages accumulated in the fields of protein modification analysis and antibody development, the company has always adhered to independent research and development innovation. Since its establishment in 2010, it has continuously introduced 11 new types of protein modification analysis services, including butyrylation, succinylation, acetylation, 2-hydroxyisobutyrylation, glutarylation, benzoylation, 3-hydroxybutyrylation, and lactylation. In addition, Jingjie Bio actively explores customers in the industrial sector, including biotechnology and new drug development companies. They have established business cooperation with well-known pharmaceutical companies such as BEIGENE, LuGu Pharmaceutical, Kunyuan Gene, and Jodas-Fortune Ocean, as well as gene testing companies. The funds raised this time will be mainly used for the following purposes: Financially, as of the years 2019, 2020, 2021, and June 30, 2022, Jingjie Bio achieved revenues of approximately 116 million, 153 million, 221 million, and 89.3254 million RMB respectively. During the same period, net profits were approximately 23.1767 million, 41.3278 million, 68.1545 million, and 9.4471 million RMB respectively.